ema400
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2015 (NCT02426411)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Type-1 angiotensin II receptorANTAGONIST
AGTR1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ema400
- ema401
- ema401
- ema401
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03094195 | Phase 2 | Jun 26, 2017 | Novartis |
| NCT02426411 | Phase 2 | Jun 1, 2015 | INC Research, Spinifex Pharmaceuticals |
| NCT02435199 | Phase 2 | Jun 1, 2015 | INC Research, Spinifex Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| INC Research | For profit | 2 | 0 | 1 | 2015 |
| Spinifex Pharmaceuticals | For profit | 2 | 2 | 1 | 2015 |
| Novartis | For profit | 1 | 1 | 1 | 2017 |
3 organizations
Page 1 / 1